{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:31:42Z","timestamp":1779924702299,"version":"3.53.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["847912"],"award-info":[{"award-number":["847912"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","award":["BECA SEOM_CANCERGASTR22_1"],"award-info":[{"award-number":["BECA SEOM_CANCERGASTR22_1"]}],"id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008963","name":"Sociedad Espa\u00f1ola de Oncolog\u00eda M\u00e9dica","doi-asserted-by":"publisher","award":["PI22\/01017"],"award-info":[{"award-number":["PI22\/01017"]}],"id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["INVES21943BRAS"],"award-info":[{"award-number":["INVES21943BRAS"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018779","name":"Fundaci\u00f3n Fero","doi-asserted-by":"publisher","award":["BECA ONCOXXI21"],"award-info":[{"award-number":["BECA ONCOXXI21"]}],"id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018779","name":"Fundaci\u00f3n Fero","doi-asserted-by":"publisher","award":["CMM_CHIARAG22_001"],"award-info":[{"award-number":["CMM_CHIARAG22_001"]}],"id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["SGR 01156"],"award-info":[{"award-number":["SGR 01156"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-22-198"],"award-info":[{"award-number":["BCRF-22-198"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-23-198"],"award-info":[{"award-number":["BCRF-23-198"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","award":["BCRF-24-198"],"award-info":[{"award-number":["BCRF-24-198"]}],"id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.esmoop.2025.105563","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:26:07Z","timestamp":1757096767000},"page":"105563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy"],"prefix":"10.1016","volume":"10","author":[{"given":"D.","family":"Pes\u00e1ntez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Bras\u00f3-Maristany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Angelats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Indacochea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cuatrecasas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Sanfeliu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fern\u00e1ndez-Esparrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Notario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"M\u00e9ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Momblan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Candia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.esmoop.2025.105563_bib1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","article-title":"Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention","volume":"20","author":"Thrift","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105563_bib2","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3748\/wjg.v28.i12.1187","article-title":"Epidemiology of stomach cancer","volume":"28","author":"Ilic","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105563_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s12325-021-01931-3","article-title":"Treatment pattern for advanced gastric cancer in Japan and factors associated with sequential treatment: a retrospective administrative claims database study","volume":"39","author":"Komatsu","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105563_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12876-022-02309-7","article-title":"Relationship between HER2 overexpression and long-term outcomes of early gastric cancer: a prospective observational study with a 6-year follow-up","volume":"22","author":"Li","year":"2022","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.esmoop.2025.105563_bib5","article-title":"Challenges and future of HER2-positive gastric cancer therapy","volume":"13","author":"Ma","year":"2023","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105563_bib6","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41416-023-02559-6","article-title":"Metabolic heterogeneity affects trastuzumab response and survival in HER2-positive advanced gastric cancer","volume":"130","author":"Wang","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2025.105563_bib7","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105563_bib8","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1056\/NEJMc2408121","article-title":"Pembrolizumab in HER2-positive gastric cancer","volume":"391","author":"Janjigian","year":"2024","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.esmoop.2025.105563_bib9","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1200\/JCO.2013.48.9070","article-title":"Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab","volume":"31","author":"Gomez-Martin","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105563_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/2159-8290.CD-17-0395","article-title":"Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma","volume":"8","author":"Pectasides","year":"2018","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105563_bib11","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1136\/gutjnl-2019-320368","article-title":"Dissecting transcriptional heterogeneity in primary gastric adenocarcinoma by single cell RNA sequencing","volume":"70","author":"Zhang","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.esmoop.2025.105563_bib12","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1200\/JCO.20.02761","article-title":"HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study","volume":"39","author":"Haffner","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105563_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103801","article-title":"Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer","volume":"75","author":"Prat","year":"2022","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105563_bib14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/jnci\/djac227","article-title":"HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1","volume":"115","author":"Bras\u00f3-Maristany","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105563_bib15","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105563_bib16","article-title":"Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world study","volume":"8","author":"Mart\u00ednez-S\u00e1ez","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105563_bib17","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3390\/cancers12071902","article-title":"ERBB2 mRNA expression and response to Ado-trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"12","author":"Griguolo","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105563_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103987","article-title":"HER2DX genomic test in early-stage HER2-positive breast cancer","volume":"9","author":"Tolaney","year":"2024","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105563_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101231","article-title":"7P Independent validation of HER2DX ERBB2 mRNA score to predict HER2-positive (HER2+), HER2-low and HER2-0 status in breast cancer","volume":"8","author":"Torres","year":"2023","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105563_bib20","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"269","key":"10.1016\/j.esmoop.2025.105563_bib21","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105563_bib22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/annonc\/mdw442","article-title":"Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment","volume":"28","author":"An","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105563_bib23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2017.10.032","article-title":"HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer","volume":"88","author":"Wang","year":"2018","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105563_bib24","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/annonc\/mdy034","article-title":"Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients","volume":"29","author":"Kim","year":"2018","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105563_bib25","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/1078-0432.CCR-17-2781","article-title":"Biomarkers of primary resistance to trastuzumab in HER2-positive metastatic gastric cancer patients: the AMNESIA case-control study","volume":"24","author":"Pietrantonio","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105563_bib26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12885-022-09335-4","article-title":"Combining gene expression analysis of gastric cancer cell lines and tumor specimens to identify biomarkers for anti-HER therapies-the role of HAS2, SHB and HBEGF","volume":"22","author":"Ebert","year":"2022","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105563_bib27","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3390\/biom9120782","article-title":"Trastuzumab specific epitope evaluation as a predictive and prognostic biomarker in gastric cancer patients","volume":"9","author":"Koh","year":"2019","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105563_bib28","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41571-021-00492-2","article-title":"Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm","volume":"18","author":"Nakamura","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105563_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-019-0737-2","article-title":"Progress and challenges in HER2-positive gastroesophageal adenocarcinoma","volume":"12","author":"Zhao","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"suppl 12","key":"10.1016\/j.esmoop.2025.105563_bib30","first-page":"PS4","article-title":"PS4-06: HER2DX ERBB2 mRNA score in first-line metastatic HER2-positive breast cancer treated with docetaxel, trastuzumab and pertuzumab: correlative analysis from CLEOPATRA phase III trial","volume":"31","author":"Cort\u00e9s","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105563_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41523-025-00753-8","article-title":"HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab","volume":"11","author":"S\u00e1nchez-Bayona","year":"2025","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105563_bib32","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S1470-2045(17)30111-0","article-title":"Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study","volume":"18","author":"Thuss-Patience","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105563_bib33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10120-018-00923-7","article-title":"Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric\/gastroesophageal junction cancer","volume":"22","author":"Shah","year":"2019","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105563_bib34","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s00432-022-04208-6","article-title":"Deviating HER2 test results in gastric cancer: analysis from the prospective multicenter VARIANZ study","volume":"149","author":"Kolbe","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105563_bib35","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/s41591-024-02992-x","article-title":"Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925014322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:00:39Z","timestamp":1772895639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925014322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2059702925014322"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105563","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2DX ERBB2 score in advanced HER2-positive gastric cancer treated with trastuzumab and chemotherapy","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105563"}}